{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:53:44Z","timestamp":1791089624800,"version":"4.1.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Sleep Medicine"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.sleep.2026.109249","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T06:05:39Z","timestamp":1788761139000},"page":"109249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Dose-response meta-analysis of dual orexin receptor antagonists on sleep parameters and implications for orexin-mediated arousal"],"prefix":"10.1016","volume":"148","author":[{"given":"Claudio","family":"Caiazza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Palagini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Toni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Maffucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Sampogna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Riemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6926-0762","authenticated-orcid":false,"given":"Andrea","family":"Fiorillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.sleep.2026.109249_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.sleep.2025.106763","article-title":"The need to prioritize\u201d Insomnia disorder\u201d in public health agendas:\u201ca wakeup call\u201d position paper from European and Canadian experts in sleep and mental health","author":"Palagini","year":"2025","journal-title":"Sleep Med"},{"issue":"1","key":"10.1016\/j.sleep.2026.109249_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41572-026-00693-y","article-title":"Insomnia disorder","volume":"12","author":"Spiegelhalder","year":"2026","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"10.1016\/j.sleep.2026.109249_bib3","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1007\/s00415-023-12112-3","article-title":"Evaluation and management of insomnia in the clinical practice in Italy: a 2023 update from the Insomnia Expert Consensus group","volume":"271","author":"Palagini","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.sleep.2026.109249_bib4","series-title":"Diagnostic and statistical manual of mental disorders, Text Revision (DSM-5-TRTM)","year":"2022"},{"issue":"6","key":"10.1016\/j.sleep.2026.109249_bib5","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.13928","article-title":"Hyperarousal in insomnia disorder: current evidence and potential mechanisms","volume":"32","author":"Dressle","year":"2023","journal-title":"J Sleep Res"},{"issue":"6","key":"10.1016\/j.sleep.2026.109249_bib6","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.neuron.2010.11.032","article-title":"Sleep state switching","volume":"68","author":"Saper","year":"2010","journal-title":"Neuron"},{"issue":"2","key":"10.1016\/j.sleep.2026.109249_bib7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41583-018-0097-x","article-title":"The neurobiological basis of narcolepsy","volume":"20","author":"Mahoney","year":"2019","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.sleep.2026.109249_bib8","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.sleep.2024.09.038","article-title":"Delphi consensus recommendations for the management of chronic insomnia in Canada","volume":"124","author":"Morin","year":"2024","journal-title":"Sleep Med"},{"issue":"2","key":"10.1016\/j.sleep.2026.109249_bib9","doi-asserted-by":"crossref","first-page":"307","DOI":"10.5664\/jcsm.6470","article-title":"Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline","volume":"13","author":"Sateia","year":"2017","journal-title":"J Clin Sleep Med"},{"issue":"6","key":"10.1016\/j.sleep.2026.109249_bib10","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.14035","article-title":"The european Insomnia Guideline: an update on the diagnosis and treatment of insomnia 2023","volume":"32","author":"Riemann","year":"2023","journal-title":"J Sleep Res"},{"issue":"17","key":"10.1016\/j.sleep.2026.109249_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26178700","article-title":"Targeting the orexin system in the pharmacological management of insomnia and other diseases: suvorexant, lemborexant, daridorexant, and novel experimental agents","volume":"26","author":"\u017be\u0142abowski","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.sleep.2026.109249_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.1070522","article-title":"Dual orexin receptor antagonists for treatment of insomnia: a systematic review and meta-analysis on randomized, double-blind, placebo-controlled trials of suvorexant and lemborexant","volume":"13","author":"Khazaie","year":"2022","journal-title":"Front Psychiatr"},{"issue":"1","key":"10.1016\/j.sleep.2026.109249_bib13","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41398-025-03439-8","article-title":"Comparative efficacy and safety of daridorexant, lemborexant, and suvorexant for insomnia: a systematic review and network meta-analysis","volume":"15","author":"Kishi","year":"2025","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.sleep.2026.109249_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.sleep.2025.106848","article-title":"Efficacy and safety of insomnia pharmacotherapies: convergent evidence from Bayesian network meta-regression and FAERS-based disproportionality analysis","author":"Liu","year":"2025","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2026.109249_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.sleep.2026.108792","article-title":"The effect of Dual Orexin Receptor Antagonists on sleep: a systematic review and pairwise meta-analysis","author":"Stefanou","year":"2026","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2026.109249_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.smrv.2021.101573","article-title":"The efficacy and safety of dual orexin receptor antagonists in primary insomnia: a systematic review and network meta-analysis","volume":"61","author":"Xue","year":"2022","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.sleep.2026.109249_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1175372","article-title":"Different doses of dual orexin receptor antagonists in primary insomnia: a Bayesian network analysis","volume":"14","author":"Xue","year":"2023","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.sleep.2026.109249_bib18","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S2215-0366(19)30217-2","article-title":"Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis","volume":"6","author":"Furukawa","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.sleep.2026.109249_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2026.103847","article-title":"Antipsychotic dose and efficacy for acute schizophrenia spectrum disorders: an updated systematic review and dose-response meta-analysis","volume":"94","author":"Furukawa","year":"2026","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.sleep.2026.109249_bib20","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"13","key":"10.1016\/j.sleep.2026.109249_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115489","article-title":"Discovery of ORN0829, a potent dual orexin 1\/2 receptor antagonist for the treatment of insomnia","volume":"28","author":"Futamura","year":"2020","journal-title":"Bioorg Med Chem"},{"issue":"3","key":"10.1016\/j.sleep.2026.109249_bib22","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsaf291","article-title":"Efficacy and safety of vornorexant in Japanese patients with insomnia: a randomized, placebo-controlled phase 3 pivotal study","volume":"49","author":"Uchiyama","year":"2026","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2026.109249_bib23","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.sleep.2026.109249_bib24","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised crossover trials (beta)","volume":"366","author":"Sterne","year":"2020","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.sleep.2026.109249_bib25","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1177\/0962280218773122","article-title":"One-stage dose\u2013response meta-analysis for aggregated data","volume":"28","author":"Crippa","year":"2019","journal-title":"Stat Methods Med Res"},{"issue":"1","key":"10.1016\/j.sleep.2026.109249_bib26","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/aje\/kwr265","article-title":"Meta-Analysis for linear and nonlinear dose-response relations: examples, an evaluation of approximations, and software","volume":"175","author":"Orsini","year":"2012","journal-title":"Am J Epidemiol"},{"issue":"2","key":"10.1016\/j.sleep.2026.109249_bib27","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/pst.432","article-title":"Fitting Emax models to clinical trial dose\u2013response data","volume":"10","author":"Kirby","year":"2011","journal-title":"Pharm Stat"},{"issue":"3","key":"10.1016\/j.sleep.2026.109249_bib28","first-page":"138","article-title":"The robust error meta-regression method for dose\u2013response meta-analysis","volume":"16","author":"Xu","year":"2018","journal-title":"JBI Evidence Implementation"},{"issue":"21","key":"10.1016\/j.sleep.2026.109249_bib29","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.1002\/sim.7372","article-title":"Measuring the statistical validity of summary meta\u2010analysis and meta\u2010regression results for use in clinical practice","volume":"36","author":"Willis","year":"2017","journal-title":"Stat Med"},{"key":"10.1016\/j.sleep.2026.109249_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v072.c01","article-title":"Multivariate dose-response meta-analysis: the dosresmeta R package","volume":"72","author":"Crippa","year":"2016","journal-title":"J Stat Software"},{"issue":"1","key":"10.1016\/j.sleep.2026.109249_bib31","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12874-019-0666-3","article-title":"A review of spline function procedures in R","volume":"19","author":"Perperoglou","year":"2019","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.sleep.2026.109249_bib32","series-title":"Package \u2018minpack. lm\u2019. Title R interface Levenberg-Marquardt nonlinear Least-Sq Algorithm found MINPACK plus support bounds","author":"Elzhov","year":"2016"},{"issue":"1","key":"10.1016\/j.sleep.2026.109249_bib33","first-page":"101","article-title":"The levenberg-marquardt algorithm","volume":"11","author":"Ranganathan","year":"2004","journal-title":"Tutoral on LM algorithm"},{"key":"10.1016\/j.sleep.2026.109249_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Software"},{"issue":"3","key":"10.1016\/j.sleep.2026.109249_bib35","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/ana.25680","article-title":"Daridorexant, a new dual orexin receptor antagonist to treat insomnia disorder","volume":"87","author":"Dauvilliers","year":"2020","journal-title":"Ann Neurol"},{"issue":"9","key":"10.1016\/j.sleep.2026.109249_bib36","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.5664\/jcsm.6116","article-title":"Suvorexant in patients with insomnia: pooled analyses of three-month data from Phase-3 randomized controlled clinical trials","volume":"12","author":"Herring","year":"2016","journal-title":"J Clin Sleep Med"},{"issue":"11","key":"10.1016\/j.sleep.2026.109249_bib37","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.5664\/jcsm.6800","article-title":"Lemborexant, A Dual Orexin receptor antagonist (DORA) for the treatment of insomnia disorder: results from a bayesian, adaptive, randomized, Double-Blind, placebo-controlled Study","volume":"13","author":"Murphy","year":"2017","journal-title":"J Clin Sleep Med"},{"issue":"2","key":"10.1016\/j.sleep.2026.109249_bib38","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1474-4422(21)00436-1","article-title":"Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials","volume":"21","author":"Mignot","year":"2022","journal-title":"Lancet Neurol"},{"issue":"21","key":"10.1016\/j.sleep.2026.109249_bib39","doi-asserted-by":"crossref","first-page":"e2222","DOI":"10.1212\/WNL.0000000000009475","article-title":"Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder","volume":"94","author":"Zammit","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.sleep.2026.109249_bib40","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.sleep.2024.07.037","article-title":"Daridorexant in Japanese patients with insomnia disorder: a phase 3, randomized, double-blind, placebo-controlled study","volume":"122","author":"Uchimura","year":"2024","journal-title":"Sleep Med"},{"issue":"12","key":"10.1016\/j.sleep.2026.109249_bib41","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.18254","article-title":"Comparison of lemborexant with placebo and Zolpidem Tartrate extended release for the treatment of older adults with insomnia disorder: a phase 3 randomized clinical trial","volume":"2","author":"Rosenberg","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"9","key":"10.1016\/j.sleep.2026.109249_bib42","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsaa123","article-title":"Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2","volume":"43","author":"K\u00e4rpp\u00e4","year":"2020","journal-title":"Sleep"},{"issue":"5","key":"10.1016\/j.sleep.2026.109249_bib43","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1474-4422(14)70053-5","article-title":"Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial","volume":"13","author":"Michelson","year":"2014","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.sleep.2026.109249_bib44","article-title":"Efficacy and safety of suvorexant for the treatment of primary insomnia among Chinese: a 6-month randomized double-blind controlled study","volume":"22","author":"Fan","year":"2017","journal-title":"Neurol Asia"},{"key":"10.1016\/j.sleep.2026.109249_bib45","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.sleep.2015.10.007","article-title":"Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 data","volume":"19","author":"Snyder","year":"2016","journal-title":"Sleep Med"},{"issue":"23","key":"10.1016\/j.sleep.2026.109249_bib46","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1212\/WNL.0b013e31827688ee","article-title":"Orexin receptor antagonism for treatment of insomnia","volume":"79","author":"Herring","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.sleep.2026.109249_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.sleep.2025.108722","article-title":"A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial of lemborexant in adults with insomnia disorder","volume":"139","author":"Mi","year":"2026","journal-title":"Sleep Med"},{"issue":"12","key":"10.1016\/j.sleep.2026.109249_bib48","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsaf170","article-title":"Efficacy and safety of daridorexant in Chinese patients with insomnia disorder: a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial","volume":"48","author":"Huang","year":"2025","journal-title":"Sleep"},{"issue":"1","key":"10.1016\/j.sleep.2026.109249_bib49","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.14302","article-title":"Pharmacokinetics, safety, and efficacy of daridorexant in Japanese subjects: results from phase 1 and 2 studies","volume":"34","author":"Uchiyama","year":"2025","journal-title":"J Sleep Res"},{"issue":"2","key":"10.1016\/j.sleep.2026.109249_bib50","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s41105-025-00628-2","article-title":"Effects of daridorexant on sleep architecture in Japanese patients with insomnia disorder: analysis of a phase II randomized controlled trial","volume":"24","author":"Yagi","year":"2026","journal-title":"Sleep Biol Rhythm"},{"issue":"1","key":"10.1016\/j.sleep.2026.109249_bib51","doi-asserted-by":"crossref","DOI":"10.1093\/sleepadvances\/zpab011","article-title":"Assessment of morning sleep propensity with lemborexant in adults with insomnia disorder in a randomized, placebo-controlled crossover study","volume":"2","author":"Mayleben","year":"2021","journal-title":"Sleep Adv"},{"issue":"6","key":"10.1016\/j.sleep.2026.109249_bib52","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.5664\/jcsm.9150","article-title":"Comparison of the effect of lemborexant with placebo and zolpidem tartrate extended release on sleep architecture in older adults with insomnia disorder","volume":"17","author":"Moline","year":"2021","journal-title":"J Clin Sleep Med"},{"key":"10.1016\/j.sleep.2026.109249_bib54","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1471-2202-14-90","article-title":"The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold","volume":"14","author":"Gotter","year":"2013","journal-title":"BMC Neurosci"},{"key":"10.1016\/j.sleep.2026.109249_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2024.100190","article-title":"On the kinetic features of orexin receptor antagonists at orexin receptors, transduction systems and receptor binding","volume":"22","author":"Hoyer","year":"2024","journal-title":"Medicine in Drug Discovery"},{"key":"10.1016\/j.sleep.2026.109249_bib56","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3389\/fnins.2013.00230","article-title":"Kinetic properties of \"dual\" orexin receptor antagonists at OX1R and OX2R orexin receptors","volume":"7","author":"Callander","year":"2013","journal-title":"Front Neurosci"},{"issue":"2","key":"10.1016\/j.sleep.2026.109249_bib57","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/cpdd.817","article-title":"Pharmacokinetics, pharmacodynamics, and safety of the dual orexin receptor antagonist lemborexant: findings from single-dose and multiple-ascending-dose phase 1 studies in healthy adults","volume":"10","author":"Landry","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"2","key":"10.1016\/j.sleep.2026.109249_bib58","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1124\/jpet.117.241422","article-title":"In vitro and in Silico characterization of lemborexant (E2006), a novel dual orexin receptor antagonist","volume":"362","author":"Beuckmann","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"10.1016\/j.sleep.2026.109249_bib59","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsz076","article-title":"Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep\/wake regulation","volume":"42","author":"Beuckmann","year":"2019","journal-title":"Sleep"},{"issue":"10","key":"10.1016\/j.sleep.2026.109249_bib60","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1007\/s00213-021-05954-0","article-title":"Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia","volume":"238","author":"Roch","year":"2021","journal-title":"Psychopharmacology"},{"issue":"12","key":"10.1016\/j.sleep.2026.109249_bib61","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1177\/02698811231215415","article-title":"Abuse potential assessment of the dual orexin receptor antagonist daridorexant in rats","volume":"37","author":"Steiner","year":"2023","journal-title":"J Psychopharmacol"},{"issue":"10","key":"10.1016\/j.sleep.2026.109249_bib62","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1007\/s00213-021-05954-0","article-title":"Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia","volume":"238","author":"Roch","year":"2021","journal-title":"Psychopharmacology (Berl)"},{"issue":"5","key":"10.1016\/j.sleep.2026.109249_bib63","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/87551225221112546","article-title":"Daridorexant: a new dual orexin receptor antagonist for insomnia","volume":"38","author":"Onge","year":"2022","journal-title":"J Pharm Technol"},{"issue":"11","key":"10.1016\/j.sleep.2026.109249_bib64","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsae098","article-title":"Effect of daridorexant on sleep architecture in patients with chronic insomnia disorder: a pooled post hoc analysis of two randomized phase 3 clinical studies","volume":"47","author":"Di Marco","year":"2024","journal-title":"Sleep"},{"issue":"5","key":"10.1016\/j.sleep.2026.109249_bib65","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S1474-4422(15)00021-6","article-title":"The neurobiology, investigation, and treatment of chronic insomnia","volume":"14","author":"Riemann","year":"2015","journal-title":"Lancet Neurol"},{"issue":"12","key":"10.1016\/j.sleep.2026.109249_bib66","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1172\/JCI32829","article-title":"Prolonged wakefulness induces experience-dependent synaptic plasticity in mouse hypocretin\/orexin neurons","volume":"117","author":"Rao","year":"2007","journal-title":"J Clin Investig"},{"issue":"5","key":"10.1016\/j.sleep.2026.109249_bib67","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1474-4422(14)70053-5","article-title":"Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial","volume":"13","author":"Michelson","year":"2014","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.sleep.2026.109249_bib68","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40263-022-00980-8","article-title":"Long-Term safety and tolerability of daridorexant in patients with insomnia disorder","volume":"37","author":"Kunz","year":"2023","journal-title":"CNS Drugs"},{"key":"10.1016\/j.sleep.2026.109249_bib69","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.sleep.2021.01.048","article-title":"Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: results from a phase 3 randomized clinical trial","volume":"80","author":"Yardley","year":"2021","journal-title":"Sleep Med"},{"issue":"1","key":"10.1016\/j.sleep.2026.109249_bib70","article-title":"Mechanisms underlying tolerance after long-term benzodiazepine use: a future for subtype-selective GABAA receptor modulators?","volume":"2012","author":"Vinkers","year":"2012","journal-title":"Adv Pharmacol Pharm Sci"},{"issue":"2011","key":"10.1016\/j.sleep.2026.109249_bib71","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1146\/annurev-pharmtox-010510-100528","article-title":"Orexin receptors: pharmacology and therapeutic opportunities","volume":"51","author":"Scammell","year":"2011","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"6","key":"10.1016\/j.sleep.2026.109249_bib72","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsz302","article-title":"Dual orexin receptor antagonists increase sleep and cataplexy in wild type mice","volume":"43","author":"Mahoney","year":"2020","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2026.109249_bib73","doi-asserted-by":"crossref","DOI":"10.1038\/srep27147","article-title":"Orexin 2 receptor antagonism is sufficient to promote NREM and REM sleep from mouse to man","volume":"6","author":"Gotter","year":"2016","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.sleep.2026.109249_bib74","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/cts.13470","article-title":"Effect of discontinuation of lemborexant following long-term treatment of insomnia disorder: secondary analysis of a randomized clinical trial","volume":"16","author":"Takaesu","year":"2023","journal-title":"Clin Transl Sci"},{"issue":"5","key":"10.1016\/j.sleep.2026.109249_bib75","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.smrv.2012.11.001","article-title":"REM sleep dysregulation in depression: state of the art","volume":"17","author":"Palagini","year":"2013","journal-title":"Sleep Med Rev"},{"issue":"2","key":"10.1016\/j.sleep.2026.109249_bib76","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.14252","article-title":"Chronic insomnia, REM sleep instability and emotional dysregulation: a pathway to anxiety and depression?","volume":"34","author":"Riemann","year":"2025","journal-title":"J Sleep Res"},{"issue":"17","key":"10.1016\/j.sleep.2026.109249_bib77","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1523\/JNEUROSCI.6506-10.2011","article-title":"Differential roles of orexin Receptor-1 and -2 in the regulation of Non-REM and REM sleep","volume":"31","author":"Mieda","year":"2011","journal-title":"J Neurosci"},{"issue":"4","key":"10.1016\/j.sleep.2026.109249_bib78","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.neuron.2017.01.014","article-title":"Neural circuitry of wakefulness and sleep","volume":"93","author":"Scammell","year":"2017","journal-title":"Neuron"}],"container-title":["Sleep Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1389945726004880?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1389945726004880?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:16:51Z","timestamp":1791087411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1389945726004880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":77,"alternative-id":["S1389945726004880"],"URL":"https:\/\/doi.org\/10.1016\/j.sleep.2026.109249","relation":{},"ISSN":["1389-9457"],"issn-type":[{"value":"1389-9457","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose-response meta-analysis of dual orexin receptor antagonists on sleep parameters and implications for orexin-mediated arousal","name":"articletitle","label":"Article Title"},{"value":"Sleep Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sleep.2026.109249","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109249"}}